Founded in 1978, Pressure Biosciences (NASDAQ: PBIO) began significant operations in 1986 and went public 10 years later in 1996, under its former name, Boston Biomedica, Inc. Today the company holds 13 U.S. patents and four foreign patents for applications of its Pressure Cycling Technology (PCT), used in the healthcare field for genomics, proteomics and nucleic acid testing with the ability to rupture cells to release significantly more proteins in fatty tissue.
The company’s PCT Sample Preparation System (PCT SPS) allows for the safe, rapid and reproducible extraction of DNA, RNA, small molecules and proteins. PCT SPS combines the company’s Barocycler NEP3229 with its PULSE Tubes to process and extract up to three samples of animal, plant or microbial samples which can be processed and extracted within minutes. The system’s computer-controlled protocols ensure consistent sample extraction.
Pressure Bioscience’s technology is applicable to various life sciences areas, drawing customers from academic laboratories, government agencies and biotechnology sectors.
The products are used to further the study of various diseases such as heart disease, strokes, cancer and diabetes. The company’s product line includes its latest product, the ProteoSolve Kit, assisting in the research of obesity; the Barocycler NEP2320, Barocycler NEP3229; and its aforementioned PULSE Tubes.
Let us hear your thoughts: Pressure BioSciences, Inc. Message Board